Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

CMEO Webcast

Premiere Date: Wednesday, September 16, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, September 16, 2021

Begin Activity Now

Faculty


Sara A. Hurvitz, MD Sara A. Hurvitz, MD (Moderator)
Professor of Medicine
University of California, Los Angeles (UCLA)
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center at UCLA
Director of Breast Oncology
Simms/Mann UCLA Center for Integrative Oncology
Los Angeles, CA

Shanu Modi, MD Shanu Modi, MD 
Associate Professor of Medicine, Department of Medicine
Weill Cornell Medical College
Associate Member
Section Head, HER2 Positive Breast Cancer, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY

Michael F. Press, MD, PhD Michael F. Press, MD, PhD 
Professor
Department of Pathology
Harold E. Lee Chair in Cancer Research
Norris Comprehensive Cancer Center
Keck School of Medicine
The University of Southern California
Los Angeles, CA

Statement of Need

Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course of treatment.

This CME Outfitters Live and OnDemand webcast will provide up-to-date education on this rapidly evolving field, in order to better tailor treatment strategies, leading to improved patient outcomes. Additionally, faculty will discuss COVID-19 and its impact on patients with BC.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply HER2 testing guidelines for improved treatment selection in breast cancer.
  • Evaluate clinical trial data for novel and emerging therapies for the management of patients with low HER2 expression, resistant to HER2-directed therapies, and HER3+ BC.
  • Expand use of telemedicine in BC care.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize HER2 testing guidelines for improved treatment selection in BC.
  • Evaluate clinical trial data for novel and emerging therapies for the management of patients with low HER2 expression, resistant to HER2-directed therapies, and HER3+ BC.
  • Describe ways to expand use of telemedicine in BC care.

Financial Support

Supported by an educational grant from Daiichi Sankyo, Inc.

Target Audience

Hematologists/oncologists, OB/GYNs, surgeons, pathologists, PAs, NPs, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-20-108-L01-P
Enduring: 0376-0000-20-108-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Live activity

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Hurvitz reports that she receives research support from Ambrx Inc.; Amgen Inc.; Arvinas, Inc.; Bayer; Daiichi Sankyo, Inc.; Dignitana; Eli Lilly and Company; Genentech, Inc./Roche; GlaxoSmithKline; Immunomedics, Inc.; MacroGenics, Inc.; Novartis; OBI Pharma; Pfizer Inc.; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; and Seattle Genetics, Inc. She is a consultant for NKMax America, Inc. She receives other financial or material support as a medical writer for Pfizer, Inc. and Roche.

Dr. Modi reports that she receives research suport from AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; Novartis; and Seattle Genetics, Inc. She is on the advisory committee for AstraZeneca; Daiichi Sankyo, Inc.; and MacroGenics, Inc. She is a consultant for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Seattle Genetics, Inc. She served as a speaker or a member of a speakers bureau for: AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Seattle Genetics, Inc.

Dr. Press reports that he is a consultant for AstraZeneca; Puma Biotechnology, Inc. and Zymeworks. He is on the advisory committee for Biocartis; Cepheid; Eli Lilly and Company; Lilly USA, LLC; Merck & Co., Inc.; and Novartis. He is a stock shareholder (directly purchased) of TORL Biotherapeutics, LLC. He receives other financial material support from Science Branding Communications.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TV-116-091620-65